Teligent Inc (TLGT) Just Recorded A Sigfniciant Increase

September 17, 2017 - By Marie Mckinney

The stock of Teligent Inc (NASDAQ:TLGT) is a huge mover today! The stock increased 5.74% or $0.39 on September 15, reaching $7.19. About 1.08M shares traded or 139.10% up from the average. Teligent Inc (NASDAQ:TLGT) has risen 64.58% since September 17, 2016 and is uptrending. It has outperformed by 47.88% the S&P500.
The move comes after 9 months positive chart setup for the $383.89 million company. It was reported on Sep, 17 by Barchart.com. We have $7.41 PT which if reached, will make NASDAQ:TLGT worth $11.52M more.

Wall Street await Teligent Inc (NASDAQ:TLGT) to release earnings on October, 26. After posting $-0.02 EPS for the previous quarter, Teligent Inc’s analysts now forecast -50.00 % EPS growth.

More notable recent Teligent Inc (NASDAQ:TLGT) news were published by: Globenewswire.com which released: “Teligent, Inc. Announces Second Quarter 2017 Results” on August 08, 2017, also Globenewswire.com with their article: “Teligent, Inc. to Present at Morgan Stanley 15th Annual Global Healthcare …” published on September 12, 2017, Prnewswire.com published: “Teligent, Inc. Appoints Martin Wilson To General Counsel” on April 25, 2017. More interesting news about Teligent Inc (NASDAQ:TLGT) were released by: Prnewswire.com and their article: “Teligent, Inc. Announces FDA Approval Of Erythromycin Topical Gel USP, 2%” published on July 21, 2017 as well as Seekingalpha.com‘s news article titled: “Teligent: A Speculative Growth Opportunity” with publication date: June 08, 2017.

Teligent, Inc. is a specialty generic pharmaceutical company. The company has market cap of $383.89 million. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. It currently has negative earnings. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.